ABSTRACTS

Abstract Guidelines

The ISTH is currently moving forward with holding a “hybrid” Congress in Philadelphia in 2021. A hybrid congress would be composed of both an in-person and virtual component. With the ongoing uncertainty of COVID-19, the ISTH will continue to evaluate and monitor conditions to hold an in-person meeting with the health and safety of our attendees, staff, and vendors at the forefront of our planning.

Regardless of the final organization of the Congress, we want to assure abstract submitters that we are planning to have the full set of 80 hours for oral abstract presentations associated with a traditional congress. We are also preparing various strategies to ensure optimized poster discussions.

 

Send in your abstracts from December 1, 2020 - February 2, 2021. Whether chosen for oral or poster presentation, they will have similar opportunities for reaching the target audience as in a traditional ISTH congress.

Important Dates

  • December 1, 2020:
    Abstract submission launches

  • February 2, 2021 at 17:00 EST (U.S.):
    Abstract submission closes

  • April 26, 2021:
    Abstract withdrawal deadline

  • May 14, 2021:
    Abstract titles released (only confirmed participating abstract titles)

  • May 19, 2021:
    Late-breaking abstract submission opens

  • June 2, 2021 at 17:00 EST (U.S.):
    Late-breaking abstract submission closes

  • July 2, 2021 at 09:00 EST (U.S.):
    Full text abstracts are released (excludes late-breaking)

Main Topics

  • Arterial Thromboembolism

  • Coagulation & Natural Anticoagulants

  • COVID and Coagulation

  • Diagnostics and OMICs

  • Fibrinolysis and Proteolysis

  • Hemophilia and Rare Bleeding Disorders

  • Hemostatic Systems in Cancer, Inflammation and Immunity

  • Pediatrics

  • Platelet Disorders, Von Willebrand Disease and Thrombotic Microangiopathies

  • Platelets and Megakaryocytes 

  • Vascular Biology

  • Venous Thromboembolism

  • Women’s Health

The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

Arterial Thromboembolism

  • Acute Coronary Syndromes

  • Atherosclerosis

  • Cardiovascular Risk Factors

  • Cerebrovascular Disorders

  • Peripheral Artery Disease

Coagulation and Natural Anticoagulants

  • Animal Models in Thrombosis and Hemostasis

  • Coagulation Factors and Inhibitors

  • Contact Pathway

  • Critical Care and Perioperative

  • FVIII/IX

  • Hemostasis and Organ Dysfunction

  • Microparticles

  • Protein C Pathway

  • Regulation of Coagulation

  • Tissue Factor Pathway

COVID and Coagulation

  • COVID and Coagulation, Basic Science

  • COVID and Coagulation, Clinical

Diagnostics and OMICs

  • Biomarkers of Thrombosis and Hemostasis

  • Blood Components and Management

  • Cellular Therapies

  • Epigenetics, OMICs and Bioinformatics

  • Laboratory Diagnostics

  • Nanotechnology and Novel Biomolecules

Fibrinolysis and Proteolysis

  • Fibrinogen and Factor XIII

  • Fibrinolytic Factors and Inhibitors

  • Plasminogen Activation in the CNS and Immunity

  • Thrombolytic Therapy

Hemophilia and Rare Bleeding Disorders

  • Acquired Hemorrhagic Coagulation Disorders

  • Disseminated Intravascular Coagulation

  • Hemophilia - Basic

  • Hemophilia - Clinical

  • Hemophilia Gene Therapy

  • Management of Bleeding and Trauma

  • Novel Biotherapeutics in Hemophilia

  • Rare Bleeding Disorders

Nurses

  • Nurses and Allied Health

Pediatrics

  • Bleeding in Neonates and Children

  • Thrombosis in Neonates and Children​

Platelet Disorders, Von Willebrand Disease and Thrombotic Microangiopathies

  • Acquired Thrombocytopenias

  • ADAMTS13 and TTP

  • Antiplatelet Therapy

  • HIT

  • HUS

  • Inherited Thrombocytopenias

  • Non HUS/TTP Microangiopathies

  • Platelet Antagonists and Novel Therapeutics

  • Platelet Function Disorders, Acquired

  • Platelet Function Disorders, Hereditary

  • Von Willebrand Factor Biology

  • VWF and Von Willebrand Factor Disorders - Clinical Conditions

Platelets and Megakaryocytes

  • Megakaryocytes and Thrombopoiesis

  • Platelet Function and Interactions

  • Platelet Proteomics and Genomics

  • Platelet Receptors

  • Platelet Signaling

Role of Hemostatic System in Cancer, Inflammation and Immunity

  • Coagulation Proteins Beyond Hemostasis

  • Complement and Hemostatic System

  • Infection and Hemostatic Factors

  • Platelets and Cancer

  • Platelets and Infection

  • Platelets and Inflammation

  • Proteases and Cancer

Vascular Biology

  • Blood Cells and Vessel Wall

  • Endothelial Cell Signaling

  • Inflammation and Sepsis

  • Innate and Adaptive Immunity

  • Non-coding RNAs

  • Protease Activated Receptors

  • Stem Cells and Vascular Cell Growth

Venous Thromboembolism

  • Antiphospholipid Syndrome

  • Artificial Valves

  • Atrial Fibrillation

  • Cancer Associated Thrombosis

  • Genetic Risk Factors of Thrombosis

  • Post-thrombotic Syndrome

  • Thrombophilia

  • Visceral Vein Thrombosis

  • VTE Diagnosis

  • VTE Epidemiology

  • VTE Prophylaxis

  • VTE Treatment

Women Health

  • Estrogens and Progestinics

  • Pregnancy and Pregnancy Complications

How to Submit an Abstract

  • Delegates, who would like to present their work at the congress, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee.

  • ISTH Members and Non-Members are invited to submit abstracts.

  • There are no fees to submit an abstract.

  • Abstracts can only be submitted online via the abstract submission website that can be found in the section “Abstract Guidelines” on the official ISTH 2021 Congress website. Abstracts sent by post or email will not be accepted. No exceptions will be made.

  • The submitter will be required to create a user account in order to submit an abstract. This can be done through the registration system. Once logged in you will be able to select ‘Submit an Abstract’ from the tabs at the top.

  • Abstracts can be saved in "Draft” status and be re-edited and modified until the submission deadline (February 2, 2021, 17:00 Eastern Standard Time (U.S.).

    • You can still make edits to abstracts that have been submitted, but you will need to re-submit it before the deadline to be considered.

  • The submitted/draft abstracts cannot be edited after the submission deadline.

  • Only abstracts that have been submitted properly will be considered for the congress.

  • Any technical questions regarding the submission website should be sent to isth2021@abstractserver.com. All other abstract related questions can be sent to abstracts@isth.org

 

General Guidelines

  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.

  • Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.

  • Please ensure your abstract does not contain spelling, grammar, or scientific mistakes, as it will be reproduced exactly as submitted. Linguistic accuracy is your responsibility. No proof reading will be done.

  • Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected. Similarly, do not submit a copy or close copy of an abstract under more than one (1) topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.

  • All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.

  • Those presenters who agree to have their education materials available for up to 90 days on the congress platform will be highly considered for an Oral Communication Session during the selection process. 

  • No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

ISTH Embargo Policy

You can view the ISTH Embargo Policy here.

 

Preparing an Abstract for Submission
Authors and Co-Authors

  • The first/presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.

  • The presenting author of the abstract must be registered for the meeting. 

  • The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived.

  • A maximum of 20 authors is permitted on each abstract, plus one (1) group.

  • Adding Co-authors: please fill out the family names, first names, and institution, city, country and email addresses of each co-authors.

  • NEW! Based on current ACCME guidelines, if the presenting author is employed by industry, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an Oral Communication session. This step will be done in the abstract confirmation portal; details will be included in the abstract notification.
     

Conflict of Interest

  • It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting/presenting author of an abstract is requested to declare any potential conflicts of interest for the presenting author during abstract submission.

  • NEW! If the abstract is selected for an Oral Communication session, the presenting author must enter in all disclosure information for each co-author in the abstract confirmation portal; details will be included in the abstract notification.

 
Abstract Body

  • For standardization, the acceptable length of the abstract is a maximum of 300 words. This does not include the author’s details, titles, tables and figures.

  • Title: Clearly indicate the nature of the investigation. The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.

  • Background

  • Aims

  • Methods: Which should contain sufficient information to be able to understand the experimental design, the analytical techniques and the statistics used in the study

  • Results: Which should contain objective data to answer the scientific question(s). A maximum of two total tables or figures may be submitted with this section. Please be sure to number each table and figure and cite each table and figure in the abstract text.

  • Conclusion (or Conclusions): Which should provide only conclusions of the study directly supported by the results, along with implications for clinical practice, avoiding speculation and overgeneralization.

  • Other Items for Consideration

    • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.

    • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.

    • Please indicate the funding agency of your work if applicable.

    • Abbreviations should be defined.

    • If off-label use of drugs was involved in the study, please state this clearly.

 
Table and Figures

  • Figures may be submitted with a maximum file size is 10 MB with a resolution of 300 dpi. Figures are allowed in the following formats: PNG, GIF, JPG.

  • Tables are allowed with a maximum size of 10 columns x 10 rows. Characters in your table will NOT count towards your 300 word count.

  • Tables should be added using the tool in the submitter and not as an image file.

  • Your abstract may contain two (2) graphics or tables; this can be a combination of the following: two (2) figures, two (2) tables, or one (1) figure and one (1) table.

Prior Publication

Authors will be permitted to submit their abstract to ISTH 2021 Congress and another journal/meeting as long as the data in the abstract has not been published/presented at the time of submission or will not be published prior to ISTH releasing the abstract (two weeks prior to the meeting). 

 

Abstracts submitted to regional or national hematology meetings can be submitted to the ISTH 2021 Congress for consideration for inclusion in the program.

 

If you have questions regarding prior publication, please contact us at abstracts@isth.org.

Late-Breaking Abstracts

  • Late breaking abstracts will not be submitted during the regular abstract submission process. Late breaking abstracts will be submitted following the below timeline:

    • Late Breaking Abstract Submission Site Opens: May 19, 2021

    • Late Breaking Abstract Submission Site Closes: June 2, 2021

    • Congress Dates: July 17 – 21, 2021

  • Late breaking abstracts should highlight novel studies of high impact. Abstracts submitted will be considered as a Late Breaking abstract if the study is ground breaking and includes novel data. The abstract should not have been previously published in any format.

  • The late breaking abstract deadline is not intended to be an extension of the regular submission deadline.

  • The review and selection process will be highly competitive. No more than four (4) abstracts will be selected to be featured in one (1) Oral Communication Session. If your abstract is not chosen to be included in the Late-Breaking Oral Communication Session, it will be rejected. Late-Breaking Abstract Submission will open on May 19, 2021.

  • Late-breaking abstracts selected for the Late-breaking Oral Communication Session will not be made available prior to the ISTH 2021 Congress. Late-breaking abstracts will be made available at the start of the Late-breaking Oral Communication session.

  • All accepted Late-breaking abstracts will be published as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH)

 

Language Setting of Your Keyboard
The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed.
 
To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard." Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  
 
In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.

After Submission
An international panel of experts will review the abstracts. Each abstract will be reviewed by 4-6 different experts. Abstracts may be selected for oral presentation, poster presentation, publication only or rejection. The presenting author will be notified in early-April 2021, at the email address provided during submission, about whether or not their abstract has been accepted.

The reviewers will judge the abstracts according to the following criteria:

  • Is the abstract original?

  • Does it address an important scientific question?

  • Is the abstract clearly written with all salient facts?

  • Does the work adhere to ethical guidelines?

  • Is there evidence of statistical method if appropriate?

  • Are the conclusions justified by the results?


​Please note:

  • No revisions can be made after the abstract deadline. To ensure the integrity of the review process, revisions to abstracts will not be accepted after the abstract submission deadline.

  • The review and selection process for Late Breaking Abstracts will be highly competitive. No more than four (4) abstracts will be selected to be featured in one (1) Oral Communication Session. If your abstract is not chosen to be included in the Late-Breaking Oral Communication Session, it will be rejected. Late-breaking Abstract Submission will open on May 19, 2021.

  • The best scoring abstracts will be selected for oral presentation.

  • Oral Presentation: Authors of abstracts selected for oral presentation will be informed about the date and time of the session. Presentation guidelines will be made available online.

  • Poster Presentation: Poster presenters will be informed about the date and time of the poster exhibition. Poster guidelines will be made available online. Posters will be organized within the session using the topics chosen by the submitter in the online system.

  • All accepted abstracts will be published online two weeks prior to the ISTH 2021 Congress on Friday, July 2, 2021 at 09:00 Eastern Standard Time (U.S. EST) on the ISTH 2021 iPlanner and the ISTH 2021 Abstract Searchable Database, except Late-breaking abstract which will be made available on the day of the Late-breaking Oral Communication session.

  • All accepted and confirmed abstracts will also be published as an addendum supplement to the ISTH open access journal, Research and Practice in Thrombosis and Haemostasis (RPTH) and will be made available on the ISTH 2021 Congress website after the congress. 

Withdrawal Policy
If authors wish to withdraw their abstracts from presentation or publication they are requested to notify ISTH via e-mail to abstracts@isth.org before Monday, April 26, 2021. Withdrawn abstracts will not be presented nor will these be published.

 

Travel Awards
For the ISTH 2021 Congress we will offer two possible awards for those that apply. The ISTH will maintain both the Early Career and Reach-the-World Travel Awards. For the ISTH 2021 Congress they may be available to the presenting author for the in-person component or the virtual component.

 

For those presenting authors that are awarded a Travel Award and plan to attend the ISTH 2021 Congress in-person the Travel Awards will be awarded a monetary stipend onsite to assist with travel to the congress.

For those presenting authors that are awarded a Travel Award and plan to attend the ISTH 2021 Congress virtually the Travel Awards will be awarded as a complementary registration to a limited number of presenting authors in lieu of travel assistance.

 

Click here to learn more

 

Technical Requirements
The online abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher. Cookies and JavaScript need to be enabled.

Tel: +1 919 929 3807

Fax: +1 919 929 3935
meetings@isth.org

International Society on Thrombosis and Haemostasis (ISTH) 
610 Jones Ferry Road, Suite 205 Carrboro, NC 27510 USA
© COPYRIGHT 2020. ALL RIGHTS RESERVED

  • Black Facebook Icon
  • Black Twitter Icon
  • Black LinkedIn Icon
  • Black YouTube Icon